A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients

Link to article at PubMed

J Acquir Immune Defic Syndr. 2020 Jul 22. doi: 10.1097/QAI.0000000000002452. Online ahead of print.


BACKGROUND: The effectiveness of Lopinavir/ritonavir (LPV/r) and chloroquine treatment for COVID-19 has not been verified.

METHODS: We conducted a retrospective study to summarize the clinical practices of non-severe patients with COVID-19 receiving the standard care, LPV/r or chloroquine in Beijing Ditan hospital from January 20 to March 26, 2020. The main outcome measurements include the changes of cycle threshold (Ct) values of open reading frame 1ab (ORF1ab) and nucleocapsid (N) genes by RT-PCR assay from day 1 to 7 after admission for patients receiving standard care, or after treatment being initiated for patients receiving either LPV/r or chloroquine. The proportion of developing severe illness, fever duration and the time from symptom onset to chest CT improvement and negative conversion of nucleic acid were compared.

RESULTS: Of the 129 patients included in the study, 59 received the standard care, 51 received LPV/r, and 19 received chloroquine. The demographics and baseline characteristics were comparable among the three groups. The median duration of fever, median time from symptom onset to chest CT improvement and negative conversion of the nucleic acid were similar among the three groups. The median increase in Ct values of N and ORF1ab gene for patients receiving LPV/r or chloroquine or the standard care during the treatment course was 7.0 and 8.5, 8.0 and 7.6, 5.0 and 4.0, respectively. These figures were not found significantly different among the three groups.

CONCLUSION: Antiviral therapy using LPV/r or chloroquine seemed not to improve the prognosis or shorten the clinical course of COVID-19.

PMID:32740371 | DOI:10.1097/QAI.0000000000002452

Leave a Reply

Your email address will not be published.